Good News for Tofacitinib in Recent Study of Acute Severe UC
'Tofacitinib has shown efficacy in managing ASUC, but concerns about postoperative complications have limited its adoption,' reported the authors in research published in Clinical Gastroenterology and Hepatology.
'This study shows that tofacitinib is safe and doesn't impair wound healing or lead to more infections if the patient needs an urgent colectomy, which is unfortunately common in this population,' senior author Jeffrey A. Berinstein, MD, of the Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan, told Medscape Medical News.
Recent treatment advances for UC have provided significant benefits in reducing the severity of symptoms; however, about a quarter of patients go on to experience flares, with fecal urgency, rectal bleeding, and severe abdominal pain of ASUC potentially requiring hospitalization.
The standard of care for those patients is rapid induction with intravenous (IV) corticosteroids; however, up to 30% of patients don't respond to those interventions, and even with subsequent treatment of cyclosporine and infliximab helping to reduce the risk for an urgent colectomy, patients often don't respond, and ultimately, up to a third of patients with ASUC end up having to receive a colectomy.
While JAK inhibitor therapies, including tofacitinib and upadacitinib, have recently emerged as potentially important treatment options in such cases, showing reductions in the risk for colectomy, concerns about the drugs' downstream biologic effects have given many clinicians reservations about their use.
'Anecdotally, gastroenterologists and surgeons have expressed concern about JAK inhibitors leading to poor wound healing, as well as increasing both intraoperative and postoperative complications, despite limited data to support these claims,' the authors wrote.
To better understand those possible risks, first author Charlotte Larson, MD, of the Department of Internal Medicine, Michigan Medicine, and colleagues conducted a multicenter, retrospective, case-control study of 109 patients hospitalized with ASUC at two centers in the US and 14 in France.
Of the patients, 41 were treated with tofacitinib and 68 with infliximab prior to colectomy.
Among patients treated with tofacitinib, five (12.2%) received infliximab and four (9.8%) received cyclosporine rescue immediately prior to receiving tofacitinib during the index admission. In the infliximab group, one (1.5%) received rescue cyclosporine.
In a univariate analysis, the tofacitinib-treated patients showed significantly lower overall rates of postoperative complications than infliximab-treated patients (31.7% vs 64.7%; odds ratio [OR], 0.33; P = .006).
The tofacitinib-treated group also had lower rates of serious postoperative complications (12% vs 28.9; OR, 0.20; P = .016).
After adjusting for multivariate factors including age, inflammatory burden, nutrition status, 90-day cumulative corticosteroid exposure and open surgery, there was a trend favoring tofacitinib but no statistically significant difference between the two treatments in terms of serious postoperative complications ( P = .061).
However, a significantly lower rate of overall postoperative complications with tofacitinib was observed after the adjustment (odds ratio, 0.38; P = .023).
Importantly, a subanalysis showed that the 63.4% of tofacitinib-treated patients receiving the standard FDA-approved induction dose of 10 mg twice daily did indeed have significantly lower rates than infliximab-treated patients in terms of serious postoperative complications (OR, .10; P = .031), as well as overall postoperative complications (OR, 0.23; P = .003), whereas neither of the outcomes were significantly improved among the 36.6% of patients who received the higher-intensity thrice-daily tofacitinib dose ( P = .3 and P = .4, respectively).
Further complicating the matter, in a previous case-control study that the research team conducted, it was the off-label, 10 mg thrice-daily dose of tofacitinib that performed favorably and was associated with a significantly lower risk for colectomy than the twice-daily dose (hazard ratio 0.28; P = .018); the twice-daily dose was not protective.
Berinstein added that a hypothesis for the benefits overall, with either dose, is that tofacitinib's anti-inflammatory properties are key.
'We believe that lowering inflammation as much as possible, with the colon less inflamed, could be providing the benefit in lowering complications rate in surgery,' he explained.
Regarding the dosing, 'it's a careful trade-off,' Berinstein added. 'Obviously, we want to avoid the need for a colectomy in the first place, as it is a life-changing surgery, but we don't want to increase the risk of infections.'
In other findings, the tofacitinib group had no increased risk for postoperative venous thrombotic embolisms (VTEs), which is important as tofacitinib exposure has previously been associated with an increased risk for VTEs independent of other prothrombotic factors common to patients with ASUC, including decreased ambulation, active inflammation, corticosteroid use, and major colorectal surgery.
'This observed absence of an increased VTE risk may alleviate some of the hypothetical postoperative safety concern attributed to JAK inhibitor therapy in this high-risk population,' the authors wrote.
Overall, the results underscore that 'providers should feel comfortable using this medication if they need it and if they think it's most likely to help their patients avoid colectomy,' Berinstein said.
'They should not give pause over concerns of postoperative complications because we didn't show that,' he said.
Commenting on the study, Joseph D. Feuerstein, MD, of the Department of Medicine and Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, noted that, in general, in patients with ASUC who fail on IV steroids, 'the main treatments are infliximab, cyclosporine, or a JAK inhibitor like tofacitinib or upadacitinib, [and] knowing that if someone needs surgery, the complication rates are similar and that pre-operative use is okay is reassuring.'
Regarding the protective effect observed with some circumstances, 'I don't put too much weight into that,' he noted. '[One] could speculate that it is somehow related to faster half-life of the drug, and it might not sit around as long,' he said.
Feuerstein added that 'the study design being retrospective is a limitation, but this is the best data we have to date.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 days ago
- Medscape
You Are When You Eat: Microbiome Rhythm and Metabolic Health
You are when you eat? Perhaps. Similar to circadian rhythms that help regulate when we naturally fall asleep and wake up, microbial rhythms in our gut are naturally active at certain times of the day to help regulate our digestion. Researchers from the UC San Diego sought out to track these microbial rhythms to determine whether aligning the times we eat to when our gut microbes are most active can bolster our metabolic health. This alignment is known as time-restricted feeding (TRF). 'Microbial rhythms are daily fluctuations in the composition and function of microbes living in our gut. Much like how our bodies follow an internal clock (circadian rhythm), gut microbes also have their own rhythms, adjusting their activities based on the time of day and when we eat,' said Amir Zarrinpar , MD, PhD, gastroenterologist and associate professor of medicine at UC San Diego School of Medicine, and senior author of the study. Zarrinpar and his team were particularly interested in observing whether adopting the TRF approach counteracted the harmful metabolic effects often associated with consuming a high-fat diet. The study is also notable for the team's use of technology able to observe real-time microbial changes in the gut — something not previously attainable with existing metagenomics. How the Study Evolved With New Tech Researchers separated three groups of mice to analyze their microbiome activity: one on a high-fat diet with unrestricted access, another on the same high-fat diet within a TRF window of 8 hours per day, and a control group on a normal chow diet with unrestricted access. 'In mice, [their] microbial rhythms are well-aligned with their nocturnal lifestyle. For example, during their active (nighttime) period, certain beneficial microbial activities increase, helping digest food, absorb nutrients, and regulate metabolism,' said Zarrinpar. As a result, the team made sure the mice's TRF window was at night or when they would normally be awake. 'We chose an 8-hour feeding window based on earlier research showing this time period allows mice to consume the same total calories as those with unlimited food access,' said Zarrinpar. 'By controlling [the] calories in this way, we ensure any metabolic or microbial benefits we observe are specifically due to the timing of eating, rather than differences in total food intake.' But before any observations could be made, the team first needed a way to see real-time changes in the animals' gut microbiomes. Zarrinpar and his team were able to uncover this, thanks to metatranscriptomics, a technique used to capture real-time microbial activity by profiling RNA transcripts. Compared with the more traditional technique of metagenomics, which could only be used to identify which genes were present, metatranscriptomics provided more in-depth temporal and activity-related context, allowing the team to observe dynamic microbial changes. '[Metatranscriptomics] helps us understand not just which microbes are present, but specifically what they are doing at any given moment,' said Zarrinpar. 'In contrast, metagenomics looks only at microbial DNA, which provides information about what microbes are potentially capable of doing, but doesn't tell us if those genes are actively expressed. By comparing microbial gene expression (using metatranscriptomics) and microbial gene abundance (using metagenomics) across different diet and feeding conditions in [light and dark] phases, we aimed to identify how feeding timing might influence microbial activity.' Because metagenomics focuses on stable genetic material, this technique cannot capture the real-time microbial responses to dietary timing presented in rapidly changing, short-lived RNA. At the same time, the instability of the RNA makes it difficult to test hypotheses experimentally and explains why researchers haven't more widely relied on metatranscriptomics. To overcome this difficulty, Zarrinpar and his team had to wait to take advantage of improved bioinformatics tools to simplify their analysis of complex datasets. 'It took several years for us to analyze this dataset because robust computational tools for metatranscriptomic analysis were not widely available when we initially collected our samples. Additionally, sequencing costs were very high. To clearly identify microbial activity, we needed deep sequencing coverage to distinguish species-level differences in gene expression, especially for genes that are common across multiple types of microbes,' said Zarrinpar. What They Found After monitoring these groups of mice for 8 weeks, the results were revealed. As predicted, the mice with unrestricted access to a high-fat diet exhibited signs of metabolic dysfunction due to disruptions in their circadian and microbial rhythms. 'When mice have free access to a high-fat diet, their normal eating behavior changes significantly. Instead of limiting their activity and feeding to their active nighttime period, these mice begin to stay awake and eat during the day, which is their typical rest phase,' Zarrinpar explained. 'This unusual daytime activity interferes with important physiological processes. Consequently, the animals experience circadian misalignment, a condition similar to what human shift workers experience when their sleep-wake and eating cycles don't match their internal biological clocks,' he continued. 'This misalignment can negatively affect metabolism, immunity, and overall health, potentially leading to metabolic diseases.' For the mice that consumed a high-fat diet within a TRF window, metabolic phenotyping demonstrated that their specific diet regimen had protected them from harmful high-fat induced effects including adiposity, inflammation, and insulin resistance. Even more promising, the mice not only were protected from metabolic disruption but also experienced physiological improvements including glucose homeostasis and the partial restoration of the daily microbial rhythms absent in the mice with unrestricted access to a high-fat diet. While the TRF approach did not fully restore the normal, healthy rhythmicity seen in the control mice, the researchers noted distinct shifts in microbial patterns that indicated time-dependent enrichment in genes attributed to lipid and carbohydrate metabolism. Better Metabolic Health — and Better Tools for Researching It Thankfully, the latest advancements in sequencing technology, including long-read sequencing methods, are making metatranscriptomics easier for research. 'These newer platforms offer greater resolution at a lower cost, making metatranscriptomics increasingly accessible,' said Zarrinpar. With these emerging technologies, he believes metatranscriptomics will become a more standard, widely used method for researchers to better understand the influence of microbial activity on our health. These tools, for example, enabled Zarrinpar and the team to delve deeper and focus on the transcription of a particular enzyme they identified as a pivotal influence in observable metabolic improvements: bile salt hydrolase (BSH), known to regulate lipid and glucose metabolism. The TRF approach notably enhanced the expression of the BSH gene during the daytime in the gut microbe Dubosiella newyorkensis , which has a functional human equivalent. To determine why this happened, the team leveraged genetic engineering to insert several active BSH gene variants into a benign strain of gut bacteria to administer to the mice. The only variant to produce metabolic improvements was the one derived from Dubosiella newyorkensis ; the mice who were given this BSH-expressing engineered native bacteria (ENB) had increased lean muscle mass, less body fat, lower insulin levels, enhanced insulin sensitivity, and better blood glucose regulation. 'It is still early to know the full clinical potential of this new BSH-expressing engineered native bacterium,' said Zarrinpar. 'However, our long-term goal is to develop a therapeutic that can be administered as a single dose, stably colonize the gut, and provide long-lasting metabolic benefits.' Testing the engineered bacteria in obese and diabetic mice on a high-fat diet would be a next step to determine whether its potential indeed holds up. If proven successful, it could then be used to develop future targeted therapies and interventions to treat common metabolic disorders. With this engineered bacteria, Zarrinpar and his team are hopeful that it alone can replicate the microbial benefits associated with following a TRF dietary schedule. 'In our study, the engineered bacterium continuously expressed the enzyme DnBSH1, independently of dietary or environmental factors. As a result, the bacterium provided metabolic benefits similar to those seen with TRF, even without requiring the mice to strictly adhere to a TRF schedule,' said Zarrinpar. 'This suggests the exciting possibility that this engineered microbe might serve either as a replacement for TRF or as a way to enhance its beneficial effects,' he continued. 'Further studies will help determine whether combining this ENB with TRF could provide additional or synergistic improvements in metabolic health.' Looking Ahead 'As the pioneer of the single anastomosis duodenal switch which separates bile from food until halfway down the GI tract, I agree that bile is very important in controlling metabolism and glucose,' said Mitchell Roslin , MD, FACS, professor of surgery at the Donald and Barbara Zucker School of Medicine, Hempstead, New York, chief director of bariatric and metabolic surgery at Lenox Hill Hospital, who was not involved in the study. 'Using enzymes or medications that work in the GI tract without absorption into the body is very interesting and has great potential. It is an early but exciting prospect.' However, Roslin expressed some reservations. 'I think we are still trying to understand whether the difference in microbiomes is the cause or effect/association. Is the microbiome the difference or is a different microbiome representative of a diet that has more fiber and less processed foods? Thus, while I find this academically fascinating, I think that there are very basic questions that need better answers, before we look at the transcription of bacteria.' Furthermore, translating the metabolic results observed in mice to humans might not be as straightforward. 'Small animal research is mandatory, but how the findings convert to humans is highly speculative,' said Roslin. 'Mice that are studied are usually bred for medical research, with reduced genetic variation. Many animal models are more sensitive to time-restricted eating and caloric restriction than humans.' While it requires further research and validation, this UC San Diego study nevertheless contributes to our overall understanding of host-microbe interactions. 'We demonstrate that host circadian rhythms significantly influence microbial function, and conversely, these microbial functions can directly impact host metabolism,' said Zarrinpar. 'Importantly, we now have a method to test how specific microbial activities affect host physiology by engineering native gut bacteria.' Roslin similarly emphasized the importance of continued investment in exploring the microbial ecosystem inside us all. 'There is wider evidence that bacteria and microbes are not just passengers using us for a ride but perhaps manipulating every action we take.'
Medscape
5 days ago
- Medscape
Infections Common in IBD, Rates Vary by Treatment
TOPLINE: Patients with inflammatory bowel disease (IBD) experienced higher rates of mild and moderate infections. Women, smokers, those with multiple comorbidities, and those with exposure to certain IBD medications showed significantly higher rates of infections. METHODOLOGY: Researchers conducted a prospective observational study (June 2020 to July 2021) to evaluate the incidence of and risk factors for mild, moderate, and severe infections in 629 patients (mean age, 48.3 years; 58.2% women) with IBD who used an established remote monitoring platform for IBD management. They used the Patient-Reported Infections Questionnaire, a validated seven-item tool with a 3-month recall period, to collect data on 15 infection categories, including respiratory tract, urinary tract, and skin conditions and COVID-19. The presence or absence of disease activity was confirmed using a combination of monitoring questionnaire scores for patient-reported disease activity and faecal calprotectin levels. The severity of infection was categorised on the basis of the type and route of treatment as mild (self-limiting or requiring topical treatment), moderate (requiring oral treatment), or severe (requiring hospitalisation and/or intravenous treatment). Exposure to different medications, alone or in combination, was also assessed. TAKEAWAY: Overall, 991 infections were reported during 573.8 person-years of follow-up, with an overall incidence rate (IR) of 172.7 per 100 person-years, predominantly comprising mild (68%; IR, 117.5 per 100 person-years) and moderate (29.5%; IR, 50.9 per 100 person-years) infections. Women demonstrated significantly higher rates of infections than men (IR ratio [IRR], 1.70; P < .001), with increased rates of infections among current smokers vs non-smokers (IRR, 1.43; P = .004). Patients with a Charlson Comorbidity Index score > 2 had significantly higher rates of infections than those with lower scores (IRR for all infections, 1.69; P = .031). Glucocorticoid use more than doubled the rates of infections (IRR, 2.02; P = .033), and compared with no treatment, the use of JAK inhibitors, immunomodulator monotherapy, anti-TNF monotherapy, and combination therapy with anti-TNF and immunomodulators were associated with increased rates of infections. IN PRACTICE: "Clinicians should adopt a holistic approach that includes vigilant monitoring, preferably using validated tools, such as the PRIQ [Patient-Reported Infections Questionnaire], to identify patients with frequent mild or moderate infections. In addition, proactive application of preventive strategies, like vaccination, optimizing nutritional status, counselling for lifestyle modifications, and careful selection of therapies, should be used to reduce infection risk," the authors of the study wrote. SOURCE: This study was led by Ashkan Rezazadeh Ardabili, MD, Department of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, the Netherlands. It was published online on July 09, 2025, in the Journal of Crohn's and Colitis. LIMITATIONS: The study's 1‐year follow‐up coincided with COVID‐19 public health measures, likely underestimating overall rates of infections. This study was underpowered to precisely assess rare outcomes, and its real‐world design limited the control over the distribution of medication groups, especially when stratifying the analysis by IBD subtype. DISCLOSURES: This study was supported in part by an investigator-initiated research grant from Takeda. Some authors reported receiving grants, non-financial support, and research prizes and serving as speaker, advisor, and/or principal investigator for various institutions and pharmaceutical companies, including Takeda. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Health Line
14-07-2025
- Health Line
How to Live Beyond an Ulcerative Colitis Diagnosis
Getting diagnosed with ulcerative colitis means you can begin managing your symptoms and finding a treatment plan that works for you. Being diagnosed with ulcerative colitis (UC) can cause a range of emotions. On one hand, it's a relief to have an explanation for your symptoms and a plan to treat them. However, you may also worry about how this disease will affect your quality of life. Keep reading to learn how the condition may affect your routine and what simple steps you can take to regain control of your body and your lifestyle. Understand treatment options Other than surgery to remove your colon and rectum, there's no cure for UC. But several drugs can reduce the frequency of attacks and bring the disease into remission. Treating UC requires the care of an intestinal tract specialist, or gastroenterologist. There's no one-size-fits-all approach — your treatment plan will depend on whether your symptoms are mild, moderate, or severe. It's important to take your medication exactly as prescribed to benefit the most from treatment. Depending on the therapy, it can take weeks or even months for symptoms to improve. Let your healthcare team know if a medication isn't working. Some drugs are more effective than others, and your doctor may need to adjust your dosage or switch your medication. People respond differently to medications, so it's standard procedure to try more than one before you and your healthcare team figure out which is best for treating your UC. If you don't achieve remission with an anti-inflammatory or an immunosuppressant drug, you may be a candidate for biologics. This therapy — which targets the proteins that cause inflammation in your colon — can treat moderate to severe UC. If you have severe UC that doesn't respond to biologics, surgery to remove your colon may help. While it's a significant decision, surgery can provide long-term relief when other treatments haven't worked. Adjust or modify your diet There's no one diet to treat UC. The foods you eat don't cause the disease, but some may lead to a flare-up or worsen it. However, what affects one person may not affect another, which is why it's important to try to learn your food and drink triggers. If you can prevent or reduce the severity of a flare-up, you'll enjoy more of your favorite activities. Keeping a food diary can help you identify which foods trigger your symptoms, so you can make personalized adjustments that may reduce flare-ups and help you stay active and engaged in your daily life. Some people have found that eating a low fiber diet reduces loose stool and frequent bowel activity. Likewise, a lactose-free diet may decrease abdominal pain, gas, and diarrhea. Other diet and nutrition strategies to help you feel better and stay in control include: avoiding greasy or fried foods eating 5to 6 small meals daily eating foods rich in probiotics limiting caffeine, which can act as a laxative cutting out spicy foods to avoid irritating your intestinal tract Proper nutrition helps manage this disease, so talk with your doctor about taking multivitamins. A supplement can prevent vitamin deficiencies that result from removing certain foods from your diet. Be prepared when going out or traveling Flare-ups can occur unexpectedly, but they don't have to keep you from living your life. With some planning and preparation, you can stay active and enjoy the things you love. Whether you're headed to the movies, a restaurant, or another public place, it's helpful to know where the restrooms are, just in case. If you're worried about symptoms appearing suddenly, consider carrying a small kit with essentials like an extra pair of underwear and moist wipes. This kind of simple preparation can help you feel more confident and in control. If you're traveling, ensure you have enough medication to last for the duration of your trip. Forgetting your medication at home and skipping dosages can trigger a flare-up while away. If you'll be away for an extended time, consult your doctor about sending your prescription to a pharmacy in your destination city. Alternatively, get a referral to a local clinic in case you need professional healthcare while traveling. Join a support group A family history of UC increases the risk of developing the disease. But sometimes, there isn't a genetic link. If you're the only one in your family or circle of friends trying to manage UC, you may feel alone at times. Frequent bowel activity and diarrhea can cause feelings of embarrassment, and it's often easier to hide from others and avoid talking about what's going on. But shying away from social interactions can contribute to isolation. And the truth is, talking about your disease may help you feel better. If you share your feelings with people you trust and give them a chance to offer support, you may find it easier to resume activities. In addition to talking with friends and family, ask your doctor or gastroenterologist about local support groups or counseling. Connecting with others with UC can be helpful — not only for emotional support, but also for sharing practical tips and coping strategies. Maintain a positive outlook UC isn't caused by stress or anxiety, but emotional stress can sometimes worsen symptoms. Managing stress through mindful meditation, light exercise, journaling, or puzzling may help you feel calmer and more relaxed, ultimately reducing your stress levels. Even though living with UC can be challenging, having a support system and strategies for coping when flare-ups arise can make a difference. Being depressed or anxious can contribute to social isolation and the loss of interest in activities, and these feelings can occur if you're having difficulties managing your UC. If you are finding it difficult to cope with UC, talk with your healthcare team about options. They may recommend trying an antidepressant.
